SCHEDULE: Merck Entities Report Stake in Precigen

Several Merck-affiliated entities have jointly filed a Schedule 13G, reporting a combined 4.9% beneficial ownership of Precigen, Inc. common stock.

Summary

• This filing is an amendment to a Schedule 13G, indicating a joint filing by Ares Trading SA, Merck Serono SA, Merck KGaA, Darmstadt, Germany, and E. Merck KG, Darmstadt, Germany.
• The reporting persons collectively beneficially own 17,467,152 shares of Precigen, Inc. common stock.
• This ownership represents 4.9% of the class of securities.
• The percentage is based on 358,035,247 shares of common stock outstanding as of July 31, 2026, as reported in Precigen's Form 10-Q for the period ended June 30, 2026.
• The filing confirms that the securities were not acquired for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership thresholds rather than a reflection of significant operational or financial changes.

Positives

• The reporting entities collectively hold a significant stake, indicating a level of investment interest in Precigen.
• The filing confirms adherence to regulatory disclosure requirements for beneficial ownership.

Negatives

• The filing does not provide any new operational or financial performance data for Precigen.
• The information is primarily an update on ownership, not an indicator of company performance.

Risks

• The filing does not explicitly mention any risks associated with Precigen's business operations or financial health.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Precigen's future performance.

Management Comments

• The reporting persons have entered into a Joint Filing Agreement, pursuant to which they have agreed to file this Schedule 13G jointly.
• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors or other entities that acquire beneficial ownership of more than 5% of a class of a company's registered equity securities. This filing indicates a significant passive investment by several entities affiliated with Merck.

Stakeholder Impact

• Shareholders: The filing provides transparency regarding significant ownership, which can influence market perception but does not directly alter existing shareholder rights or company operations.

Next Steps

• The reporting persons will continue to file amendments to this Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Precigen, Schedule 13G, Beneficial Ownership, Ares Trading SA, Merck KGaA, Merck Serono SA, E. Merck KG, Joint Filing